tbuckley/cabot-search huggingface dataset:
IS NOVEL POWER SPIRAL ENTEROSCOPY THE HOLY GRAIL IN SMALL BOWEL ENDOSCOPIC EXPLORATION?
Authors: V.R. Donapati, R.K. Adi, R.S. Bagepally, S.R. Guduru R, B. Immaneni, A.K. Mannava
Journal: Endoscopy (2022)

Aims The initial assessment of the novel motorised Power spiral Enteroscopy in it’s potential to explore the entire small bowel in a shorter duration.
Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer
Authors: Neal A. Patel, Robert E. Reiter
Journal: Journal of Clinical Oncology (2022)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. January 11, 2022 ARTICLE CITATION DOI: 10.1200/JCO.21.02940 Journal of Clinical Oncology - published online before print February 24, 2022 PMID: 35201894 Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer Neal A. Patel, MD1xNeal A. PatelSearch for articles by this author, and Robert E. Reiter , MD, MBA1,2xRobert E. ReiterSearch for articles by this author Show More 1Institute of Urologic Oncology, University of California, Los Angeles, CA2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA https://doi.org/10.1200/JCO.21.02940 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTImpact of a Novel Molecular Imaging Modality, Prostate Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Robert E. ReiterStock and Other Ownership Interests: ImaginAbConsulting or Advisory Role: Astellas PharmaSpeakers' Bureau: Janssen Oncology, Genomic Health, ImaginAb, Bayer Schering PharmaPatents, Royalties, Other Intellectual Property: patents surrounding discovery of PSCA and N-cadherin, owned by UCLANo other potential conflicts of interest were reported. Companion Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups
Neutrophil phenotypes and functions in cancer: A consensus statement
Authors: Daniela F. Quail, Borko Amulic, Monowar Aziz, Betsy J. Barnes, Evgeniy Eruslanov, Zvi G. Fridlender, Helen S. Goodridge, Zvi Granot, Andrés Hidalgo, Anna Huttenlocher, Mariana J. Kaplan, Ilaria Malanchi, Taha Merghoub, Etienne Meylan, Vivek Mittal, Mikael J. Pittet, Andrea Rubio-Ponce, Irina A. Udalova, Timo K. van den Berg, Denisa D. Wagner, Ping Wang, Arturo Zychlinsky, Karin E. de Visser, Mikala Egeblad, Paul Kubes
Journal: The Journal of Experimental Medicine (2022)

Neutrophils are the first responders to infection and inflammation and are thus a critical component of innate immune defense. Understanding the behavior of neutrophils as they act within various inflammatory contexts has provided insights into their role in sterile and infectious diseases; however, the field of neutrophils in cancer is comparatively young. Here, we summarize key concepts and current knowledge gaps related to the diverse roles of neutrophils throughout cancer progression. We discuss sources of neutrophil heterogeneity in cancer and provide recommendations on nomenclature for neutrophil states that are distinct in maturation and activation. We address discrepancies in the literature that highlight a need for technical standards that ought to be considered between laboratories. Finally, we review emerging questions in neutrophil biology and innate immunity in cancer. Overall, we emphasize that neutrophils are a more diverse population than previously appreciated and that their role in cancer may present novel unexplored opportunities to treat cancer.
Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype
Authors: Megan A. Clarke, Susan S. Devesa, Anne Hammer, Nicolas Wentzensen
Journal: JAMA Oncology (2022)

Uterine cancer incidence has been increasing, particularly rates of aggressive, nonendometrioid subtypes, which are disproportionately higher among non-Hispanic Black women. The association of subtype-specific trends with uterine cancer mortality and with the role of tumor subtype and stage at diagnosis with racial disparities in uterine cancer deaths at the population-based level are not known.To estimate histologic subtype- and stage-specific uterine cancer mortality rates by race and ethnicity, corrected for hysterectomy.This cohort study used the US Surveillance, Epidemiology, and End Results-18 Incidence-Based Mortality database, representing approximately 26% of the US population and including deaths that occurred from 2000 to 2017. Hysterectomy correction was based on hysterectomy prevalence data from the Behavioral Risk Factor Surveillance System. Uncorrected and corrected rates associated with uterine corpus cancer cases diagnosed between 2000 and 2017 and uterine corpus cancer deaths occurring between 2010 and 2017 were age-adjusted to the 2000 US standard population and are expressed per 100 000 person-years, and annual percent changes in rates were calculated using log-linear regression. Data analysis was performed from March 10 to May 20, 2021.Tumor histologic subtype, cancer stage at diagnosis, and race and ethnicity.Among 208 587 women diagnosed with uterine cancer during 2000-2017 (15 983 [7.7%] were Asian; 20 302 [9.7%] Black; 23 096 [11.1%] Hispanic; and 149 206 [71.5%] White individuals), there were 16 797 uterine cancer deaths between 2010 and 2017, corresponding to a hysterectomy-corrected mortality rate of 15.7 per 100 000 person-years. Hysterectomy-corrected rates were highest among Black women, overall, by histologic subtype and stage at diagnosis. Among all women, uterine corpus cancer mortality rates increased significantly by 1.8% (95% CI, 1.5%-2.9%) per year from 2010 to 2017, as did rates of nonendometrioid carcinomas (2.7%; 95% CI, 1.8%-3.6%), with increases occurring in Asian (3.4%; 95% CI, 0.3%-6.6%), Black (3.5%; 95% CI, 2.2%-4.9%), Hispanic (6.7%; 95% CI, 1.9%-11.8%), and White women (1.5%; 95% CI, 0.6%-2.4%). In contrast, endometrioid carcinoma mortality rates remained stable.The findings of this cohort study suggest a significant increase of nonendometrioid uterine carcinoma mortality rates, aligning with recent incidence trends. The factors associated with these trends are not well understood and require more investigation of possible mechanisms. Despite stable incidence rates, endometrioid cancer mortality rates have not decreased over the past decade at the population level, suggesting limited progress in treatment for these cancers. The substantial disparities in uterine corpus cancer mortality rates among non-Hispanic Black women cannot be fully explained by subtype distribution and stage at diagnosis.
Home modifications and disability outcomes: A longitudinal study of older adults living in England
Authors: Tarani Chandola, Patrick Rouxel
Journal: The Lancet Regional Health - Europe (2022)

There is limited evidence on the protective effect of housing modifications on disability outcomes among older adults. We examined whether external and internal housing modifications reduce the risk of a range of disability outcomes among older adults living in England.We analysed adults aged 60 and over from the English Longitudinal Study of Ageing, initially recruited in 2002/03. The longitudinal sample consisted of 32,126 repeated observations from 10,459 individuals across 6 waves with an average follow-up of 11·3 years. Participants were asked if their homes had external (widened doorways, ramps, automatic doors, parking and lift) and internal (rails, bathroom/kitchen modifications, chair lift) housing modifications. Mobility impairment was measured through reported difficulties in 10 activities including walking, climbing, getting up, reaching and lifting. Five disability outcomes were analysed (falls in the previous two years, pain, poor self-rated health, no social activities, and moving home within next two years) using two-way fixed effect models, controlling for key risk factors for disability.Greater mobility impairments increased the probability of falls, pain and poor self-rated health although this effect was significantly moderated by external housing modifications. Among older adults with severe mobility impairments, external housing modifications reduced the probability of falls by 3% (1%-6%), pain by 6% (4%-8%), and poor health by 4% (2%-5%). Moreover, external housing modifications reduced the probability of no social activities by 6% (5%-7%) and moving home by 4% (2%-5%) even among those without any mobility impairments. Internal housing modifications had similar, but less consistent effects on the disability outcomes.There was strong evidence that external housing modifications protected against a range of disability outcomes. Studies on reducing disability in ageing populations need to consider the role of housing modifications as key interventions to promote healthy ageing in place.Economic and Social Research Council ES/R008930/1 and ES/S012567/1.
ENDOSCOPIC ULTRASOUND; HIGHLY EFFECTIVE IN THE INVESTIGATION OF LYMPHADENOPATHY OF UNKNOWN CAUSE
Authors: W. Ahmed, D. Joshi, A. Prachalias, A. Patel, P. Harrison, K. Menon, P. Srinivasan, J. Devlin, D. Reffitt
Journal: Endoscopy (2022)

Aims Endoscopic ultrasound (EUS) guided tissue acquisition is an indispensable tool in the diagnostic pathway of upper GI and hepatobiliary cancer. We sought to assess the utility in guiding patient management in patients presenting with lymphadenopathy of unknown cause.
IMPACT OF PERORAL-CHOLANGIOSCOPY TO PLAN SURGERY FOR PROTRUDING BILIARY LESIONS: REPORT OF THREE CASES
Authors: S.M. Milluzzo, A. Tringali, V. Perri, G.M. Ettorre, A. Laurenzi, F. Ardito, F. Giuliante, G. Costamagna
Journal: Endoscopy (2022)

Protruding biliary lesions are uncommon findings during radiological or endoscopic evaluation of biliary tree.
GASTRIC PERORAL ENDOSCOPIC MYOTOMY (G-POEM) FOR REFRACTORY GASTROPARESIS: 12-MONTH FOLLOW-UP RESULTS FROM AN ITALIAN TERTIARY ACADEMIC HOSPITAL
Authors: A. Barchi, F.V. Mandarino, F. Azzolini, D. Esposito, P. Biamonte, L. Fanti, E. Viale, S. Danese
Journal: Endoscopy (2022)

Aims The aim of this prospective observational study is to evaluate the efficacy of the G-POEM in 12 months-follow up in patients with gastroparesis refractory to medical therapy.
PERFORMANCE OF A CONVOLUTIONAL NEURAL NETWORK FOR THE DETECTION OF BLOOD OR HEMATIC RESIDUES IN ENTEROSCOPY: A PROOF-OF-CONCEPT STUDY
Authors: P. Marílio Cardoso, M.J. Mascarenhas Saraiva, J. Afonso, T. Ribeiro, A.P. Andrade, H. Cardoso, J. Ferreira, G. Macedo
Journal: Endoscopy (2022)

Aims Artificial intelligence algorithms have shown promising results when applied to different endoscopic techniques. The application of Convolutional Neural Networks (CNN) for detection of lesions in double-balloon enteroscopy (DBE) has not been explored. We aimed to develop and test a CNN-based algorithm for automatic detection of blood or hematic residues in DBE exams.
ENDOSCOPIC MANAGEMENT OF COMPLETE MAIN PANCREATIC DUCT TRANSECTION IN A YOUNG CHILD
Authors: R. Medas, P. Moutinho-Ribeiro, G. Macedo
Journal: Endoscopy (2022)

A 11-year-old female suffered blunt abdominal trauma with a school chair and presented in emergency room with epigastric pain and vomits. On admission, abdominal tenderness was noted and laboratory workup showed mild elevation of pancreatic enzymes. Abdominal ultrasonography revealed irregularity in the pancreatic neck with adjacent fluid, suspicious of parenchymal laceration. Computed tomography confirmed complete transection of main pancreatic duct (MPD) (grade IV injury). Early endoscopic retrograde cholangiopancreatography was performed with successful bridging of the disruption and insertion of a plastic stent. After 14 weeks with good clinical evolution, stent was removed and integrity of MPD confirmed by endoscopic ultrasonography.
SECONDARY TUMORS OF THE PANCREAS: A MULTICENTER ANALYSIS OF CLINICOPATHOLOGICAL AND ENDOSONOGRAPHIC FEATURES
Authors: M. Spadaccini, S.F. Crinò, A. Fantin, D. Rahal, E. Manfrin, F. Gavazzi, S. Bozzarelli, M.C. Conti Bellocchi, R. Maselli, A. Anderloni, A. Fugazza, L. Frulloni, A. Repici, S. Carrara
Journal: Endoscopy (2022)

Aims Many extrapancreatic tumors may secondarily involve the pancreas(3-12%). However, most evidences are based on retrospective analysis of autopsies and surgical series.The aim of this study was to describe clinical, endosonographic,and pathological features of secondary tumors of the pancreas,along with their therapeutic approach and related outcomes.
96P PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2- breast cancer
Authors: J.I. Lopez Velazco, S. Manzano, K. Elorriaga, A. Lahuerta Martinez, L.A. Álvarez, I. Etxabe Azkue, M. Huarte Martinez, E. Buch, J. Giménez Climent, V. Quiroga Garcia, S. Aragón, L. Paré, A. Prat, I. Alvarez Lopez, M. Muñoz Caffarel, A. Urruticoechea
Journal: Annals of Oncology (2022)
5P Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer
Authors: H.K. Ahn, K. Park, S.H. Sim, K.J. Suh, M.H. Kim, W-Y. Park, Y-L. Choi, S-A. Im, K.H. Jung, Y.H. Park
Journal: Annals of Oncology (2022)
EUS-DIRECTED TRANSGASTRIC ERCP (EDGE) VERSUS LAPAROSCOPY-ASSISTED ERCP (LA-ERCP) IN PATIENTS WITH ROUX-EN-Y GASTRIC BYPASS (RYGB): A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: V. Lira De Oliveira, I. Mendonça Proença, E. Silvino Do Monte Junior, W. Marques Bernardo, D. Turiani Hourneaux de Moura, M. Cândido Hemerly, E.Y. Yvamoto, P.H. Boraschi Vieira Ribas, I. Braga Ribeiro, E. Guimaraes Hourneaux De Moura
Journal: Endoscopy (2022)

Aims Performing ERCP is challenging in patients with RYGB and it is not well defined which is the best approach. Although EDGE is arising as a new technique with promising and similar outcomes compared to LA-ERCP, better quality of evidence about this question is still required.
ENDOSCOPIC RESECTION FOR TYPE III G-NETS: A SYSTEMATIC REVIEW
Authors: A. Tringali, D. Costa, D.G. Adler
Journal: Endoscopy (2022)

Aims The traditional management of type III Gastric Neuroendocrine Tumors (G-NETs) has been radical surgical resection due to higher risk of metastasis and poor prognosis compared with type I and II. Recent studies highlighted the role of endoscopic resection in a selected group of type III G-NETs. We performed a systematic review to assess the role of endoscopic treatment in this setting.
BOWEL PREPARATION FOR SMALL BOWEL CAPSULE ENDOSCOPY: EFFICACY OF STANDARD REGIMEN WITH LOW VOLUME (2L) PEG VERSUS VERY LOW VOLUME (1L) PEG AND ASCORBATE
Authors: F. Cavallaro, P. Eidler, G.E. Tontini, R. Caccia, C. Gentile, M. Maregatti, N. Nandi, A. Piagnani, A. Rimondi, L. Scaramella, M. Vecchi, L. Elli
Journal: Endoscopy (2022)

Aims ESGE guidelines recommend purgative bowel preparations with 2L of PEG for small bowel capsule endoscopy (SBCE). We have compared the efficacy of a standard formulation of 2L-PEG solution (SELG-ESSE) versus a very low volume solution (1L-PLENVU​ Macrogol 3350+Sodium ascorbate+sodium sulfate+Ascorbic acid+Electrolytes) already adopted for large bowel preparation.
AN OBJECTIVE, FULLY AUTOMATED BARRETT’S RISK PREDICTION ASSAY OUTPERFORMS MOST PATHOLOGISTS IN RISK STRATIFYING BARRETT’S ESOPHAGUS WITH LOW GRADE DYSPLASIA
Authors: A.M. Khoshiwal, N.F. Frei, L.C. Duits, R.E. Pouw, E. Bossart, M. Wilhelm, R. Critchley-Thorne, J.J. Bergman
Journal: Endoscopy (2022)

Aims Low-grade dysplasia (LGD) is the best predictor of malignant progression in Barrett’s Esophagus (BE). LGD is over-diagnosed, therefore guidelines recommend expert histological revision. TissueCypher is an objective, automated BE risk prediction assay, previously validated. We aimed to evaluate the predictive value of TissueCypher in BE patients with community-based LGD and to benchmark its performance against an international panel of pathologists.
EUS-GUIDED TREATMENT OF GI BLEEDING SECONDARY TO GASTRIC VARICES USING COILS AND 2-OCTYL CYANOACRYLATE INJECTION
Authors: M. Lajin
Journal: Endoscopy (2022)

An 82-year-old female with liver cirrhosis secondary to NASH presented with upper GI bleeding and was found to have gastric varices IGV 1 with a fibrin clot. No esophageal varices or a feeding vessel were identified.
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
Authors: Pan Su, Liuling Xiao, Lingqun Ye, Zhuo Wang, Wei Xiong, Qiang Wang, Xingzhe Ma, Miao Xian, Maojie Yang, Youli Zu, Sai Ravi Pingali, Jianfei Qian, Qing Yi
Journal: Journal of Hematology & Oncology (2022)

Abstract Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that regulates cell proliferation, survival, and migration. However, its role on human multiple myeloma (MM) cells is largely unknown. In this study, we show that LPA, which is highly elevated in MM patients, plays an important role in protecting human MM cells against proteasome inhibitor (PI)-induced apoptosis. LPA bound to its receptor LPAR2 activated its downstream MEK1/2-ERK1/2 signaling pathway and enhanced oxidative phosphorylation (OXPHOS) in mitochondria in MM cells. Increased OXPHOS activity produced more NAD + and ATP, reduced proteasome activity, and enhanced protein folding and refolding in endoplasmic reticulum (ER), leading to induction of MM resistance to PIs. Importantly, inhibiting LPAR2 activity or knocking out LPAR2 in MM cells significantly enhanced MM sensitivity to PI-induced apoptosis in vitro and in vivo. Interestingly, primary MM cells from LPA-high patients were more resistant to PI-induced apoptosis than MM cells from LPA-low patients. Thus, our study indicates that LPA-LPAR2-mediated signaling pathways play an important role in MM sensitivity to PIs and targeting LPA or LPAR2 may potentially be used to (re)sensitize patients to PI-based therapy.
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
Authors: Matteo Lambertini, Shona Fielding, Sibylle Loibl, Wolfgang Janni, Emma Clark, Maria Alice Franzoi, Debora Fumagalli, Carmela Caballero, Luca Arecco, Sharon Salomoni, Noam F Ponde, Francesca Poggio, Hee Jeong Kim, Cynthia Villarreal-Garza, Olivia Pagani, Shani Paluch-Shimon, Alberto Ballestrero, Lucia Del Mastro, Martine Piccart, Jose Bines, Ann H Partridge, Evandro de Azambuja
Journal: JNCI Journal of the National Cancer Institute (2022)

Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients.APHINITY (NCT01358877) is an international, placebo-controlled, double-blind randomized phase III trial in HER2-positive early BC patients investigating the addition of pertuzumab to adjuvant chemotherapy plus trastuzumab. The prognostic and predictive value of age on invasive disease-free survival (IDFS) as continuous and dichotomous variable (aged 40 years or younger and older than 40 years) was assessed. A subpopulation treatment effect pattern plot analysis was conducted to illustrate possible treatment-effect heterogeneity based on age as a continuous factor.Of 4804 included patients, 768 (16.0%) were aged 40 years or younger at enrollment. Median follow-up was 74 (interquartile range = 62-75) months. Young age was not prognostic either as dichotomous (hazard ratio [HR] = 1.06, 95% confidence interval [CI] = 0.84 to 1.33) or continuous (HR = 1.00, 95% CI = 1.00 to 1.01) variable. Lack of prognostic effect of age was observed irrespective of hormone receptor status and treatment arm. No statistically significant interaction was observed between age and pertuzumab effect (Pinteraction = 0.61). Adding pertuzumab improved IDFS for patients in the young (HR = 0.86, 95% CI = 0.56 to 1.32) and older (HR = 0.75, 95% CI = 0.62 to 0.92) cohorts. Similar results were observed irrespective of hormone receptor status. Subpopulation treatment effect pattern plot analysis confirmed the benefit of pertuzumab in 6-year IDFS across age subpopulations.In patients with HER2-positive early BC treated with modern anticancer therapies, young age did not demonstrate either prognostic or predictive value, irrespective of hormone receptor status.
EFFICACY OF PANCREATIC STENTS IN A REAL-WORLD PRACTICE: 10-YEAR RETROSPECTIVE COMPREHENSIVE STUDY
Authors: P. Nicolaou, M. Velegraki, A. Psistakis, D. Arna, A. Mpitouli, M. Fragaki, E. Voudoukis, A. Theodoropoulou, E. Vardas, G. Paspatis
Journal: Endoscopy (2022)

Aims Recent data have shown an increase in the incidence of [post- endoscopic retrograde cholangio-pancreatography (ERCP) pancreatitis] (PEP) among hospitalized patients having ERCP. Pancreatic duct stent (PDS) placement seems to facilitate common bile duct (CBD) access and reduces the rate of PEP. However, endoscopists, feel uncomfortable placing a PDS. Most information regarding PDS comes from randomized control trials. In this study, we present a retrospective analysis of prospectively collected data, focusing on the effectiveness of PDS placement in assisting CBD cannulations and in preventing PEP, in real world practise.
DYE ANOTHER DAY: DYE-BASED CHROMOENDOSCOPY VERSUS I-SCAN VIRTUAL CHROMOENDOSCOPY IN LONG-STANDING UC: A MULTICENTER PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
Authors: P. Sinonquel, A. Jans, M. Pierick, T. Seerden, S. Sloth, J.G. Karstensen, G. De Hertogh, I. Demedts, H. Willekens, S. Vermeire, R. Bisschops
Journal: Endoscopy (2022)

Aims Long-standing ulcerative colitis (UC) has an increased risk for developing colorectal dysplasia and neoplasia. Dye-based chromoendoscopy (DCE) and virtual chromoendoscopy (VCE) increase detection of neoplastic lesions. However, limited data are available on the impact of i-scan VCE for UC neoplasia detection. We undertook a prospective randomized controlled trial to compare the neoplasia detection between DCE and i-scan in patients with long-standing UC.
ACCURACY OF AAR, APRI, FIB-4 AND MELD SCORES AS PREDICTORS OF A VARICEAL SOURCE AMONG CIRRHOTIC PATIENTS PRESENTING WITH UPPER GASTROINTESTINAL BLEEDING
Authors: V. Papastergiou, M. Mela, A. Christidou, K. Arvanitis, T. Georgiadi, A. Trikola, A. Tsatsa, F. Almpani, G. Karampekos, C. Chatzievangelinou, K. Katopodi, N. Viazis, E. Archavlis, G. Mantzaris
Journal: Endoscopy (2022)

Aims In patients with cirrhosis admitted with upper gastrointestinal bleeding (UGB), identification of a variceal source prior to endoscopy would be clinically useful. We determined the accuracy of aspartate aminotransferase to alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4) and model for end-stage liver disease (MELD) in identifying a variceal origin of UGB in cirrhotic patients.